ReviewFrontiers in cell and developmental biology2026
Piezo1-mediated mechanotransduction and metabolic regulation in bone health: molecular mechanisms and implications for bone disorders.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone continuously adapts to mechanical forces to maintain structural integrity, yet the molecular sensors that initiate this process have long remained undefined. The identification of the mechanosensitive ion channel Piezo1 has provided a pivotal molecular basis for understanding skeletal mechanotransduction. This review summarizes current advances in elucidating the unique structural features and force-gating mechanisms of Piezo1, and highlights its role as a central mechanoreceptor coordinating mechanical responses within bone tissue. We further delineate the multidimensional downstream signaling networks activated by Piezo1 and discuss the complex crosstalk among these pathways. The pathological consequences of Piezo1 dysregulation in major orthopedic disorders are examined, along with the therapeutic potential and challenges of targeting Piezo1 as a novel "mechanopharmacological" strategy. Collectively, this review provides an integrated framework for understanding the molecular foundations of bone mechanotransduction and identifies Piezo1 as a promising target for developing innovative treatments for orthopedic diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.